For laboratory and research use only. Not for human consumption.
Home > Uncategorized > Does CBL-514 Actually Work? What the Human Trials Measured

The human data show a measurable effect on fat under the abdominal skin. The jump from that result to “melts belly fat” skips the most interesting part of the story.

What did CBL-514 actually do?

CBL-514 is an investigational small molecule designed for localized fat reduction. In a randomized Phase 2 study of 76 participants, the researchers used ultrasound to measure how much abdominal subcutaneous fat changed. Eight weeks after the final session, 16 of 23 participants with available data in the CBL-514 group met the study’s 150 mL reduction threshold, compared with 0 of 16 in the placebo group. That is 69.6% of the treated participants assessed at that visit. The trial originally randomized 76 people, and 39 contributed to that comparison. Gold et al., Aesthetic Surgery Journal

Phase 2 · Eight weeks after the final treatment

Met the 150 mL localized fat-reduction threshold

CBL-514
16 / 23
69.6% of assessed participants
Placebo
0 / 16
0% of assessed participants
39 of 76 randomized participants contributed to this follow-up comparison. Gold et al., Aesthetic Surgery Journal

What does 150 mL of fat loss mean?

It is an ultrasound-based estimate of volume change under the skin in the studied abdominal area. A percentage of participants crossing that threshold tells you how common that measurement was in the analyzed group. It does not tell you how much weight anyone lost, how their entire waist looked, or how much fat changed around their organs.

Did one treatment do it?

Across follow-up visits, 12 of the 28 treated participants who reached the 150 mL threshold did so after a single treatment session. The denominator here is responders. A session involved multiple clinician-administered injections. The data tell us something about how quickly a subset responded under trial conditions. Published Phase 2 results

What did the MRI study add?

A separate randomized Phase 2b study enrolled 108 adults. At 12 weeks after the final treatment, 23 of 30 people in the CBL-514 analysis and 7 of 37 in the placebo analysis had at least a one-grade improvement on the clinician’s abdominal fat scale. The researchers also found a difference on MRI for subcutaneous fat. Forty-two people discontinued early across the two groups, which matters when interpreting how confidently the analyzed results apply to everyone who started. Lorenc et al., Aesthetic Surgery Journal

What do before-and-after photos prove?

Photos can illustrate a visible change. To judge how well an intervention performs, ask how cases were selected, whether lighting and posture were standardized, how much time elapsed, and whether weight or other interventions changed. A dramatic photo can leave all four questions unanswered. Imaging and controlled ratings are more informative about the average result. Texture, evenness and durability deserve their own measurements.

What would strengthen the case?

The two pivotal SUPREME studies are designed to build the evidence for localized abdominal fat reduction. Look for the prespecified endpoints, the number of people included in each analysis and longer follow-up data. Anyone claiming that CBL-514 is the next tesamorelin still has to explain the difference between fat under the skin and fat around the organs. SUPREME-01 · SUPREME-02 · Xcel’s CBL-514 vs. tesamorelin guide

Related research: CBL-514 side effects and injection-site firmness · Phase 2 study registration (NCT04575467)

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top